Tichakunda Mharazanye: A New Year, New Challenges, And New Milestones
Tichakunda Mharazanye, Pharmacy student at RIMT University, shared on LinkedIn about a recent article he and his colleague co-authored, adding:
”A new year, new challenges, and new milestones
The start of this year came with its fair share of pressure, tight deadlines and moments of selfdoubt.
Staying consistent, focused and curious helped me push through and l am grateful to begin the year by sharing my latest review publication.
Our work explores hemophilia beyond clotting factors, focusing on albumin as an underappreciated prognostic and diagnostic marker.
The review highlights how albumin reflects disease burden, influences bleeding severity and joint outcomes, and plays a key role in the pharmacokinetics of modern hemophilia therapies opening doors for more personalized prophylaxis.
Grateful for the learning process, the resilience it builds, and the opportunity to contribute to advancing patient-centered care in hemophilia.”
Title: Hemophilia And Albumin: Quantitative Analysis For Prognostic And Diagnostic Applications
Authors: Tichakunda Xavier Mharazanye, Shaun Muponda
Read the Full Article on The International Journal of Engineering Development and Research
More winner stories featured in Hemostasis Today.
-
Feb 2, 2026, 09:16Eyiuche Ezigbo Calls for Stronger VWD Awareness and Better Care in LMICs
-
Feb 2, 2026, 09:04Nicolas de Prost։ Plasma Exchange in Severe ANCA-Associated Vasculitis With DAH
-
Feb 2, 2026, 08:56Bartosz Hudzik on Cancer With ACS: Big Step Forward for Cardio-Oncology
-
Feb 2, 2026, 08:35Karine Kocharian on Armenia-Led WHA Resolution on Hemophilia at WHO Executive Board
-
Feb 2, 2026, 07:12The 2026 Application Cycle for ASH’s International Outreach Initiative is Now Open – ASH
-
Feb 1, 2026, 13:32Shiny K. Kajal: A Series On Reaching the Diagnosis of Immune Thrombocytopenia
-
Feb 1, 2026, 13:26Mary Cushman: Association of Atrial Fibrillation with Risk of Incident Cognitive Impairment
-
Feb 1, 2026, 13:23Abdulrahman Katib: Extended Low-Dose DOAC May Reduce VTE Recurrence
-
Feb 1, 2026, 13:22Jeff June: The Stroke That Wasn’t New – Why ‘Cryptogenic’ Often Means Undetected